Haskap and Endurance Running Performance

April 5, 2022 updated by: Northumbria University

The Influence of Haskap Berry on Exercise Performance

This study will employ a randomised, double-blind, placebo-controlled, independent groups experimental design. Submaximal, maximal and 5 km time trial running performance will be assessed before and after supplementation with haskap berry or a placebo.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Participants will consume haskap berry powder or an isocaloric placebo for 7 days. They will be required to run on a treadmill before and after supplementation to asses the influence on the intervention on aerobic performance parameters. Other performance parameters such as blood lactate, heart rate, ratings of perceived exertion and respiratory variables will also be monitored throughout the various elements of the exercise trials.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
      • Newcastle Upon Tyne, United Kingdom, NE18ST
        • Northumbria University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • healthy non-smoking males
  • completed a 5 km run (in less than 25 minutes) within the 6 weeks prior to the study

Exclusion Criteria:

  • female
  • allergies to fruit or dairy, currently taking any nutritional supplements (e.g. vitamins, antioxidant, herbal or sports enhancing supplements) or medication that might affect the study outcome
  • history of gastrointestinal, renal or cardiovascular disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Haskap berry
A commercially available haskap berry freeze-dried) powder
Dietary supplement: Haskapa
Haskapa Ltd, Oxford, UK
Placebo Comparator: Placebo
Black cherry KoolAid (Kraft Foods, USA) with added maltodextrin to match carbohydrate and calorie content
Dietary supplement: Placebo
isocaloric to the haskap powder

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
5km time trial
Time Frame: Change from baseline at 7 days
time to complete the trial (seconds)
Change from baseline at 7 days
V̇O2peak test
Time Frame: Change from baseline at 7 days
time to exhaustion (seconds)
Change from baseline at 7 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood lactate response during submaximal tests, maximal and time trial
Time Frame: Change from baseline at 7 days
lactate (mmol/L)
Change from baseline at 7 days
rating of perceived exertion during submaximal tests, maximal and time trial
Time Frame: Change from baseline at 7 days
RPE (/20)
Change from baseline at 7 days
heart rate during submaximal tests, maximal and time trial
Time Frame: Change from baseline at 7 days
(BPM)
Change from baseline at 7 days
VO2 during submaximal tests, maximal tests
Time Frame: Change from baseline at 7 days
(oxygen uptake - relative ml/kg/min and absolute l/min)
Change from baseline at 7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Northumbria University

Collaborators

Mibelle Group Biochemistry
Haskapa Ltd

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 12, 2021

Primary Completion (Actual)

November 8, 2021

Study Completion (Actual)

December 8, 2021

Study Registration Dates

First Submitted

April 6, 2021

First Submitted That Met QC Criteria

April 6, 2021

First Posted (Actual)

April 8, 2021

Study Record Updates

Last Update Posted (Actual)

April 13, 2022

Last Update Submitted That Met QC Criteria

April 5, 2022

Last Verified

April 1, 2021

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 26514

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

Data will be held by on a secure data based by the PI and made available to others but in line with contractual agreements with the funder and legal requirements of General Data Protection Regulations (GDPR) in the UK.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Exercise Performance

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe